World Psoriasis Day: Chronic disease awareness and treatment realities

World Psoriasis Day is a global healthcare awareness event observed on October 29 every year. In 2026, the International Federation of Psoriasis Associations (IFPA) set the theme as "Look Beyond My Skin," calling on people to look beyond skin lesions and focus on the overall health and quality of life of people with psoriasis.

The theme itself points to a fact that has long been underestimated: psoriasis is never as simple as an extra layer of scales on the skin.

Psoriasis is an immune-mediated, systemic chronic inflammatory disease and is not contagious. Estimates from the Guideline for Primary Care of Psoriasis (2022), issued by the Chinese Medical Association, show that more than 7 million people in China have psoriasis.

Alongside this high prevalence is a high level of stigma. Because of visible skin lesions, people with psoriasis often face avoidance, misunderstanding and even differential treatment from others. Some suffer significant psychological stress, experiencing self-denial, social withdrawal and even depression, anxiety and suicidal ideation. Misunderstanding and prejudice constitute another burden of the disease beyond the skin.

Skin lesions are only the tip of the iceberg. Redness and scaling are the visible manifestations of psoriasis, but the chronic inflammation driving these lesions is not confined to the skin. It can affect the joints, metabolic health and mental well-being. Psoriatic arthritis is one of the most common comorbidities. Without timely intervention, chronic inflammation can cause irreversible joint damage, potentially leading to deformity and disability.

If patients focus only on surface skin symptoms, they can easily overlook comorbidity risks. The Expert Consensus on Chronic Disease Management of Psoriasis, published in 2025, explicitly defines psoriasis as a systemic disease and calls on clinicians to look beyond skin lesions and proactively screen for and manage comorbidities such as cardiometabolic diseases and mental health conditions, shifting from "treating the skin" to "managing the whole body."

At present, treatment goals for psoriasis have been upgraded from symptom relief to the pursuit of skin clearance.

PASI (Psoriasis Area and Severity Index) is a standardized tool used to measure psoriasis severity. PASI 90 means a 90% improvement in a patient's PASI score compared with baseline, indicating near-complete clearance of psoriasis symptoms.

PASI 90 (near-complete clearance) and even PASI 100 (complete clearance) have become important benchmarks in clinical evaluation, and biologics and small-molecule targeted therapies have achieved therapeutic breakthroughs to a certain extent. But psoriasis remains incurable, and long-term chronic disease management is key.

Advances in treatment philosophy must ultimately be translated into long-term, standardized disease management. Sustained treatment, regular assessment and proactive comorbidity screening are all indispensable.

Only when "looking beyond the skin" becomes a shared principle in both clinical practice and public awareness will people with psoriasis be seen as more than their visible skin symptoms, and their condition be fully recognized and taken seriously as a systemic disease.

For more:

Health Talk: Targeted therapy promises hope for psoriasis treatment